NS5 (900 amino acids) exerts three different enzymatic activities. 9 The MTase activity protects viral mRNA from degradation by 5′-exoribonucleases and ensures their recognition by eukaryotic translation initiation factor. 10 The N-terminal MTase domain (residues 1-262, guanosine-5′-triphosphate-binding site, S-adenosylmethionine binding site, and NS3 protease interacting site) is connected through a ten-residue linker to the C-terminal RNA-dependent RNA polymerase (RdRp) domain formed by residues 273-900. 11 In turn, the RdRp domain is formed by three subdomains called fingers (273-315, 416-496, and 543-600), palm (497-542, 601-705), and thumb (706-900). 12 The active center of the enzyme is defined by the conserved GDD protein motif located in the palm domain. The amino acid sequence between residues 320 and 405 includes two nuclear localization sequences that are recognized by cellular factors, allowing protein transport to the nucleus. In conjunction with other viral proteins and host cell proteins, the NS5 polymerase domain promotes the formation of double-stranded RNA intermediates, both positive and negative sense. Negativesense strands serve as templates for the DENV RdRp to synthesize new positive-sense genomic RNA. 13, 14 RNA viruses, such as DENV, are the only organisms that possess enzymes with RdRp activity that is essential for their replication. The lack of RdRps in human cells as wells as in other animal species makes these polymerases an attractive antiviral target. 15 Current polymerase inhibitors belong to one of two types of molecules: first, nucleoside/nucleotide analogs (NIs) that function as RNA chain terminators 16 and second, nonnucleoside inhibitors which bind to different sites of the catalytic binding site of the enzyme, blocking the conformational switch from polymerase initiation to elongation or impeding the processivity of polymerase elongation. 17 In the literature, we can find examples of shortfalls and side effects of some of the NIs against the DENV polymerase. 18 Sometimes due to the lack of selectivity, NIs may have off-target effects on other polymerases such as mitochondrial DNA polymerase-γ, resulting in mitochondrial toxicity. 19, 20 The first reported allosteric inhibitor of DENV RdRp (NITD-1 compound, IC 50 =7.2 µM) was identified by means of high-throughput screening using a primer extension-based assay; the second was modified at the N-sulfonylanthranilic acid lead (NITD-2 compound, IC 50 =0.7 µM) 21 to selectively inhibit DENV-2 polymerase. NITD-29, a photoreactive derivative of NITD-2 (IC 50 =1.5 µM), has been used to map the compoundbinding site on the protein and, therefore, define its regulatory allosteric site. 21 Mass spectrometry of the ultraviolet cross-linked NITD-29/NS5 complex and molecular docking simulations have helped to further define the allosteric binding pocket near the residues Arg737, Thr413, and Met343 located at the RNA template tunnel. Thus, in light of these findings, it could be assumed that the inhibitory effect of these compounds is due to their ability to compete with the RNA template in the RNA template tunnel. 21 Unfortunately, these three compounds are inactive in cell culture. 21 In this context, we performed an in silico study to find new potential NS5 RdRp efficient agonists from a chemical library built with molecules sharing 70% structural similarity with NITD-1, NITD-2, and NITD-29 (~47,473 compounds recorded in the PubChem database 22 ) together with another chemical library of natural products (~325,319 compounds recorded in the SuperNatural II database 23 ). The best scoring compounds were compared with NITD inhibitors based on their ability to bind to DENV NS5 RdRp at the RNA template tunnel. In addition to this, compounds that showed the best binding scores were also evaluated for their pharmacodynamics, pharmacokinetics, and toxicity properties. At the end of the study, 39 compounds passed the selection process. These compounds scored better than NITD-1, NITD-2, and NITD-29, which suggests that these 39 compounds could overcome some of the problems experienced with NITD molecules, such as their inability to inhibit NS5 RdRp in live cell systems. Our in silico approach Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com
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investigation of putative inhibitors for the DenV rdrp provides the basis for subsequent in vitro and in vivo studies to test these newly identified DENV NS5 RdRp inhibitor candidates. ). However, in all structures, several residues were missing. Herein, the three-dimensional (3D) atomic coordinates for these amino acid sequences were obtained by constructing a model, using a homology modeling approach, for the RdRps of each of the four serotypes of DENV. Three 3D theoretical models of each UniProt dengue NS5 RdRp were built at Swiss-Model server 27 using the crystallographic structures of 4C11, 3VWS, 4V0Q, and 5DTO (Table 1) as templates. Arg737, Thr413, and Met343 or equivalent positions in the different protein sequences have been used to define the ligand-binding site. 21 For each model, water molecules, ions, or inhibitors were removed.
Materials and methods
The two-dimensional (2D) structures of 47,473 compounds from the PubChem database 22 and 325,319 molecules of natural compounds from the SuperNatural II database 23 were downloaded in spatial data file format. To handle the large number of ligand structures, we used a script 28 to convert 2D spatial data files into individual 3D structures in mol2 format using Marvin Suite 6.0 from ChemAxon (http:// www.chemaxon.com). Mol2 files were converted into pdbqt format using the Python script "prepare_ligand4.py" included in the AutoDockTools-1.5.7.rc1. 29 
Docking procedure
Prior to initiating the docking procedure, the protein (receptor) and ligand structures should be prepared. 28 All of the NS5 RdRp modeled protein structures were then subjected to geometry optimization using the repair function of the FoldX algorithm. 30 We in silico analysis of pharmacokinetic parameters and toxicity potential properties
Molecular descriptors, such as the topological polar surface area (TPSA), molecular weight (MW), the estimated logarithm (base 10) of the solubility measured in mol/L (logS), the estimated logarithm (base 10) of the partition coefficient between n-octanol and water (logP), the number of hydrogen bond acceptors, the number of hydrogen bond donors, the violations of Lipinski's rule of five 32 (Ro5 violations), the drug score (DrugScore), and the fragment-based druglikeness (Druglikeness), were calculated using DataWarrior v4.2.2 software (Allschwil, Switzerland). 33 The in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of all compounds were calculated using admet-SAR 34 In all cases, the unresolved residues are located in the RNA template tunnel, that is, the target site of our molecular docking experiments. Therefore, we generated the structural models for the NS5 RdRp protein sequences of DENV-3 as well as for the other three serotypes DENV-1, -2, and -4 ( Table 1) .
The protein sequences of NS5 RdRp of DENV-1 to -4 are highly conserved, with a minimum identity of 75% ( Figure 1 ). The sequences close to the amino acids that define the allosteric binding proteins (Arg737, Thr413, and Met343) are especially conserved, except near the DENV-3 Thr413 site. The results of Niyomrattanakit et al strongly indicate that NITD-29 was cross-linked to Met343 within the RdRp domain of NS5 and the sequence alignment showed that this position is absolutely conserved among the four serotypes of DENV. Docking and molecular simulation suggest that the compound binds to the RNA template formed between the finger and thumb subdomains. 21 Arg737 is conserved among mosquito-borne flavivirus NS5. NITD-29 compound inhibits RdRp activity through competing with RNA template in the RNA template tunnel. 21 With these sequences, three 3D models were generated (Table 1; Figure 1 ) by homology modeling (in automated mode 27 ) as the first step to perform molecular docking experiments.
ns5 rdrp-ligand molecular docking analysis
The "induced-fit" Koshland theory states that the active site of the protein is continually reshaped by interactions with the ligands, as the ligands interact with the protein. Therefore, ligand and receptor should be treated as flexible during molecular docking. 35 However, due to limitations in the 35 Also, AutoDock Vina uses in its scoring function the AMBER force field, which computes the terms of the contributions of van der Waals interactions, hydrogen bonding, electrostatic interactions, conformational entropy, and desolvation. 36 In the current study, 3D models of NS5 RpRd of the four serotypes of DENV were docked with two sets of compounds: molecules sharing 70% structural similarity with NITD-1, NITD-2, and NITD-29 21 and 37,840 compounds from the SuperNatural II 23 database with optimum pharmacokinetic and toxicological profiles. Tables 2 and 3 show the free energy variation (∆G) calculated using AutoDocK/Vina for the best docking scores, obtained for the NITD-related compounds and the SuperNatural II database compounds, respectively. In addition, hydrogen bonds and direct contacts based on van der Waals radii for compounds with the lowest free energy variations (∆G −10.5 kcal/mol) are available at http://docking. umh.es/. The calculated K D (K D = exp ∆G/RT ) for compounds with ∆G −10.5 kcal/mol is in the nanomolar or subnanomolar range that was used as a threshold to filter the docking results. 28 Therefore, ∆G values represent the first filter in the selection of putative inhibitors among the compounds studied. Additional filters were applied before proposing the final candidates. The free energy variation is a representative value of the number and intensity of the atomic interactions between the receptor (protein) and the ligand, and can thus be considered a baseline comparison for the selection of lead compounds Notes: The name of each ligand was obtained from the Pubchem database (https://pubchem.ncbi.nlm.nih.gov/). 22 The name of the compounds niTD-1, -2, and -29 was taken from niyomrattanakit et al. 21 The table shows the estimated binding free energy variation 31 (mean ± sD). The maps of the interacting residues of the protein with the best ligands and ∆g values among the candidate compounds are available at http://docking.umh.es/ Abbreviations: ns5, nonstructural protein 5; rdrp, rna-dependent rna polymerase; sD, standard deviation.
in the process of drug design. 28 Several compounds have ∆G values in the range of −10.5 to −10.0 kcal/mol (see full list at http://docking.umh.es/). Interestingly, the calculated ∆G values for all of the tested compounds against 3D models of DENV-3 NS5 RdRp are greater than −10 kcal/mol. Calculated ∆G values for NITD-1, -2, and -29 against all DENV serotypes are worse than those of the selected compounds in Tables 2 and 3 . On the other hand, we must remember that these compounds are often inactive in cell culture. 21 Thus, additional filters were applied on these selected compounds (Tables 2 and 3 ) to further characterize them in terms of pharmacokinetics and toxicity.
Prediction of ADMET profiles
In addition to its efficiency to inhibit the target protein, other factors such as absorption, biodistribution, rate at have a reasonable probability of being well absorbed, their calculated logP value must not be greater than 5.0. 33 Low solubility of a compound negatively impacts its absorption and, consequently, its biodistribution. Therefore, compounds with a calculated logS (logarithm base 10 of the solubility measured in mol/L) less than −4.0 were discarded. 33 Compounds with fragment-based druglikeness 0 and a drugscore (calculated as a combination of druglikeness, calculated logP, calculated logS, MW, and toxicity risks) 0.5 were also discarded. Most orally administered drugs have an MW of 500, a calculated logP 5, five or fewer hydrogen bond donor sites, and ten or fewer hydrogen bond acceptor which it is metabolized, excretion, and toxicity (ie, ADMET profile) upon its administration contributes to the overall success of a drug candidate. 37 Moreover, it is recognized that employing computational ADMET, in combination with in vivo and in vitro predictions in early stage in the drug discovery process, helps to reduce the number of potential safety problems. 38 In the next selection step, different paramaters were calculated to predict which compounds from Tables 2 and 3 (Lipinski's rule of five) . 32 Molecules violating more than one of these rules were ruled out. Also, mutagenicity, tumorigenicity, irritancy, and reproductive effects calculated with DataWarrior software 33 were used to further identify compounds with low tendency for toxicity. Table 4 shows the compounds which satisfied all of the criteria described above, which reduced the number of putative NS5 RdRp inhibitors to 39 compounds, which is 0.010% of all compounds in the two databases screened in this study. Figure 2 shows the calculated ∆G and molecular formula for the 39 selected compounds against each of the four serotypes of DENV. The calculated ∆G for the selected compounds is lower (ie, potentially better candidates) for DENV-2 and -4 and higher for DENV-3. Each compound interacts with multiple residues of the protein (Figure 3 ) after docking to the binding site of the RNA template tunnel. The interaction maps for the best compounds (∆G −10.5 kcal/mol) were calculated and are available at http://docking.umh.es/. The TPSA has been correlated with passive molecular transport through membranes; therefore, TPSA is able to predict transport properties of drugs. Usually, compounds passively absorbed and with TPSA 140 Å 2 are likely to exhibit high oral bioavailability. According to Zhao et al, 39 the percentage of absorption can be estimated using the lineal equation: % of absorption =109-0.345× TPSA. Using this formula, the calculated percentages of absorption for selected compounds ranged between 70.86% and 92.85% (Table 4) . What is the behavior of NITD-1, -2, and -29 compounds in relation to the above parameters? None of these three compounds satisfied all of the criteria imposed in this study to select potential DENV NS5 RdRp inhibitors. NITD-1 and -29 have low percentages of absorption (66% and 56%, respectively) ( Table 4) . Also, their calculated drug score value is less than 0.5 and their druglikeness is less than 0 (Table 4) . The MW of NITD-29 is 500 Da, a violation of Lipinski's rule of five. NITD-2 presents a percentage of absorption of 72%; however, its logS value is less than −4. The low aqueous solubility of drug candidates is a significant hurdle in many drug development projects.
We calculated additional pharmacokinetic properties following Cheng et al 34 (Table 5) . Almost all of the selected compounds showed optimum results for predicted human intestinal absorption and some compounds did so for transportation through blood-brain barrier and Caco-2. Also, the selected compounds showed no inhibitory side effects in terms of renal cation transport. The cytochrome P450 protein family catalyzes the oxidation of drugs and xenobiotics, generating more soluble compounds that are more readly removable from the body. 40 These enzymes are expressed in the liver, small intestine (reducing drug bioavailability), lungs, placenta, and kidneys. Most of the selected putative inhibitors (Table 5) did not serve as substrates for cytochrome 2C9 and 2D6, whereas almost all of them were found to act as substrates for cytochrome P450 3A4. Inhibitors of cytochrome P450 decrease the enzymatic activity of these enzymes in a dose-dependent manner and promote the accumulation of drugs to toxic levels; therefore, it is desirable that the selected compounds do not serve as inhibitors of cytochrome P450.
Most of the compounds included in Table 5 satisfy this condition.
Today it is very useful to predict the risk of toxicity of drug candidates with bioinformatics tools. 37 The toxicity risk predictor software identifies functional group similarity of the query molecule with the in vitro-and the in vivo-validated molecules included in software's built-in database; thus, similarity indicates a potential risk of toxicity. Table 6 presents the toxicity screening results for the selected compounds against DENV NS5 RdRp. None of the compounds presented potentially risks of tumorigenicity, mutagenicity, for reproductive function, or irritation. 33 Similarly, the selected compounds were negative for AMES toxicity, did not potentially inhibit human ether-a-go-go-related genes, or exhibited no properties that posed significant toxicity risk for humans. The human ether-a-go-go-related gene channel is a voltage-gated potassium channel in cardiac cells, and is essential for cardiac repolarization. With the inhibition of this channel, the electrical depolarization and repolarization of the heart ventricles can be extended, leading to potentially fatal cardiac malfunction.
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Conclusion
The selected putative DENV NS5 RdRp inhibitors identified and characterized in this in silico study showed strong theoretical binding affinity (high negative free energy variation, ∆G), as determined by molecular docking against the binding site at the RNA template tunnel for the four DENV serotypes. This, to a great extent, is explained by the multiple sites of interaction of these compounds (Figure 3) with DENV NS5 RdRp. The selected compounds bind to the allosteric site located near the amino acids Met343, Arg737, and Thr413 in a similar way to NITD-29. 21 Also, most of the selected compounds presented favorable druggability and optimum ADMET profiles, which suggests that as drug candidates, they will exhibit favourable traits, such as optimal absorption and biodistribution, compound stability, or low toxicity, all of which are critical for the success of a drug candidate. Further in vitro and in vivo studies will be required to confirm whether the in silico predicted ability of the selected compounds to inhibit DENV NS5 RdRp can be used to reduce DENV in live biological systems and strictly select those with the best potential to be used in real case scenarios. We believe that the information presented here will be useful for other laboratories interested in developing inhibitors against the NS5 RdRp of DENV. Table 6 Predicted toxicity assessment of selected compounds against the ns5 rdrp 
